Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Combination of Toripalimab and JS004 Therapy for ccRCC
- Conditions
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT06690697
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 88
- Registration Number
- NCT06532084
- Locations
- 🇷🇺
RM Gorbacheva Research Institute, Saint Petersburg, Russian Federation
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 150
- Registration Number
- NCT06527495
- Locations
- 🇪🇬
NLI, Shibīn Al Kawm, Menoufia, Egypt
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT06482086
- Locations
- 🇨🇳
West China hospital, Chengdu, Sichuan, China
A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
- Conditions
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06474663
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase 2, Randomized, Placebo Controlled Study Investigating the Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-01-26
- Target Recruit Count
- 60
- Registration Number
- NCT06227221
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
- Conditions
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Children's Hospital of Soochow University
- Target Recruit Count
- 500
- Registration Number
- NCT06221683
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳XiangYa Hospital Central South University, Changsha, Hunan, China
🇨🇳Children's Hospital of Soochow University, Suzhou, Jiangsu, China
Influence of Sarcopenia in Hepatocellular Carcinoma Patients
- Conditions
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 600
- Registration Number
- NCT06177496
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 200
- Registration Number
- NCT05889949
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT05822752
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Denver Midtwon /ID# 254163, Denver, Colorado, United States
🇮🇹IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 253247, Bologna, Emilia-Romagna, Italy
🇺🇸Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313, Prescott Valley, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.